Equity
€1.7m ▲ 11.3%
DR. MARLEEN SMET has made a profit in every financial year since 2007.
DR. MARLEEN SMET
Lifetime
20 annual accounts with figures on one time axis, 26 filings since 2001Gross marginpeak €461,543 (2026)
€461,543▲ 4.8%
Resultpeak €320,758 (2026)
€320,758▲ 4.1%
Equitypeak €1.7m (2026)
€1.7m▲ 11.3%
Debts
€15,362▼ 67.6%
Board1 name since 2022
1 directorSMET Marleen
Documentsfilings and deeds
10-10-202621 days before the deadline
2026micro format
Dividend €152,487Debts from €47,397 to €15,362
Key points
from the 2026 annual accountsFilings
26 annual accounts since 2001
The last five annual accounts were filed 17 to 24 days before the end of the period.
Position in the sector
99.1%
Higher solvency than 95% of companies in human health. Sector median 71.6% · 451 companies.
Checked score
96
Excellent
Financially stronger than 70% of micro companies in human health (NACE 86)
Probability in this band: under 0.55%
Bankruptcy probability within 12 months
< 0.1% Very low
0%0.5%1.5%4%10%≥ 25%
The dashed line is the sector median: < 0.1% across 24,179 companies (NACE 86, micro).
Fewer than 1 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
Last 24 months
12-2024: < 0.1%
01-2025: < 0.1%● unchanged vs 12-2024
02-2025: < 0.1%● unchanged vs 01-2025
03-2025: < 0.1%● unchanged vs 02-2025
04-2025: < 0.1%● unchanged vs 03-2025lowest value
05-2025: < 0.1%● unchanged vs 04-2025
06-2025: < 0.1%● unchanged vs 05-2025
07-2025: < 0.1%● unchanged vs 06-2025
08-2025: < 0.1%● unchanged vs 07-2025
09-2025: < 0.1%● unchanged vs 08-2025
10-2025: < 0.1%● unchanged vs 09-2025highest value
11-2025: < 0.1%● unchanged vs 10-2025
12-2025: < 0.1%● unchanged vs 11-2025
01-2026: < 0.1%● unchanged vs 12-2025
02-2026: < 0.1%● unchanged vs 01-2026
03-2026: < 0.1%● unchanged vs 02-2026
04-2026: < 0.1%● unchanged vs 03-2026
05-2026: < 0.1%● unchanged vs 04-2026
06-2026: < 0.1%● unchanged vs 05-2026
07-2026: < 0.1%● unchanged vs 06-2026
08-2026: < 0.1%● unchanged vs 07-2026
09-2026: < 0.1%● unchanged vs 08-2026
10-2026: < 0.1%● unchanged vs 09-2026
11-2026: < 0.1%● unchanged vs 10-2026
Financial strengthStrong
Score breakdown
lowers risk
Sector: Human health activities (NACE 86)
Liquidity: current ratio 124.41, cash €832,339
Equity €1.7m (99.1% of total assets)
Size: total assets €1.7m
Calculation
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 86, micro). It does better than 82% of them on solvency, 95% on liquidity, 50% on profitability and 54% on growth.
The bankruptcy probability was computed on 05-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
The probability rests on the annual accounts with balance sheet date 31-03-2026.
Of the companies with a bankruptcy probability in the very low class on 30-06-2025, 0.1% went bankrupt within twelve months.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Comparable companies, two years later
In July 2024, 20,136 companies had the same profile as DR. MARLEEN SMET has now. Each dot stands for 51 companies, two years later.
95.0%
were still trading
4.7%
stopped another way
0.2%
went bankrupt
That fits the bankruptcy probability of DR. MARLEEN SMET itself: < 0.1% within 12 months.
Test of the method
The method was tested on the 497,446 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 3.0% | 3.1% |
| 10 | 5.6% | 6.2% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 20,136 companies, not a prediction for DR. MARLEEN SMET. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit of up to €150,000 on 30-day terms is acceptable
Short-term debt is 0.8% and cash 49.6% of total assets. 0.9% of the assets are financed with debt and provisions.
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
5 signals, none raises the risk
Five signals.
lowers riskneutral
neutral · Latest accounts filed on time
The financial year that closed on 31-03-2026 was due by 31-10-2026 and was filed on 10-10-2026, 21 days ahead of the deadline.
NBB · 10 filingsDeviation from the deadline
2026
21 days early
2025
21 days early
2024
20 days early
2023
17 days early
2022
24 days early
2021
23 days early
2020
31 days early
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
The company filed its last 7 accounts on average 22 days before the deadline. In the sector (NACE 86), the median for financial year 2024 was 7 days before the deadline, and 36% of those companies filed late.
Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-03-2027 and is due by 31-10-2027. Nothing is late today. The company usually files around 10 October (5 of the last 5 accounts filed within 30 days either side of that date).
Companies Code · seven monthsWhere today falls in the filing period
06-11-2026 today31-03-2027 year end31-10-2027 deadline
Recent changes
Registered in the Peppol Directory
Reachable for e-invoices through 0208:0472133147
Incorporation
published on 28-06-2000 · Gazette deed
Comparable companies
same main activity, similar in size and age| Company | Total assets | Gross margin | Solvency | Staff |
|---|---|---|---|---|
| DR. MARLEEN SMET Evergem | €1.7m | €461,543 | 99.1% | - |
| DOKTER P. VERTONGEN Wielsbeke | €1.7m | €483,390 | 91.2% | - |
| CABINET MEDICAL DOCTEUR PAUL JONARD Gerpinnes | €1.6m | €449,880 | 85.1% | - |
| DR. G. SCHOLS Bonheiden | €1.5m | €444,187 | 55.2% | - |
| LUX - OTOLOGIE Fauvillers | €1.8m | €462,453 | 99.0% | - |
| CARDIOBLOU Namur | €1.6m | €472,123 | 73.3% | - |
| Gryspeerdt Stefaan Roeselare | €1.5m | €455,109 | 50.2% | - |
These companies have the same main activity as DR. MARLEEN SMET: specialist medical practice (NACE 86220). They are comparable in size and age: total assets between €1.5m and €1.8m, founded between 1998 and 2003.
Official details
Source: KBO- Status
- Active since 16-06-2000Normal situation
- Activity
- Specialist medical practiceNACE 86220and 1 other
- Financial year end
- 31 March
- Peppol
- Reachable since 20-12-2025
Annual accounts to 31-03-2026
- Turnover
- ≈ €710,000estimated
- Total assets
- €1.7m▲ 8.8%
- Filing
- Filed on 10-10-2026, 21 days before the end of the filing period
Insights on DR. MARLEEN SMET
DR. MARLEEN SMET files the micro format. That format states no turnover. The gross margin rose from €105,164 in 2007 to €461,543 in 2026.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about DR. MARLEEN SMET
- What is the company number of DR. MARLEEN SMET?
- The company number of DR. MARLEEN SMET is 0472.133.147. The VAT number is the same number with BE in front: BE 0472.133.147.
- Where is DR. MARLEEN SMET based?
- The registered office is at Schoonstraat 25, 9940 Evergem.Company details
- What does DR. MARLEEN SMET do?
- According to the KBO register, the main activity is specialist medical practice (NACE 86220).
- What is the legal form of DR. MARLEEN SMET?
- DR. MARLEEN SMET is a private limited company (BV).
- When was DR. MARLEEN SMET founded?
- DR. MARLEEN SMET was founded on 16-06-2000.
- Is DR. MARLEEN SMET still active?
- Yes, DR. MARLEEN SMET is an active enterprise in the KBO register.
- What is the turnover of DR. MARLEEN SMET?
- The turnover in financial year 2026 is ≈ €710,000. This figure is estimated from the gross margin of €461,543 and 36 comparable companies (NACE 862). It probably lies between €640,000 and €890,000.Financials
- Is DR. MARLEEN SMET profitable?
- In financial year 2026, DR. MARLEEN SMET made a profit of €320,758.
- Where can I find the annual accounts of DR. MARLEEN SMET?
- DR. MARLEEN SMET filed 26 annual accounts with the National Bank of Belgium, the latest for financial year 2026.
- When are the next annual accounts of DR. MARLEEN SMET due?
- DR. MARLEEN SMET must file the annual accounts for financial year 2027 by 31-10-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check Compare this company with its sector.Sector benchmark See what changed in the latest annual accounts.What changed
See how customers, suppliers and banks see your own company and what to improve first.